Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Bio-Rad Laboratories, Inc. (NYSE: BIO).

Full DD Report for BIO

You must become a subscriber to view this report.


Recent News from (NYSE: BIO)

Bio-Rad Laboratories (BIO) Q1 2018 Results - Earnings Call Transcript
Bio-Rad Laboratories, Inc. (BIO) Q1 2018 Earnings Call May 08, 2018 5:00 pm ET Executives Christine A. Tsingos - Bio-Rad Laboratories, Inc. Norman D. Schwartz - Bio-Rad Laboratories, Inc. John Hertia - Bio-Rad Laboratories, Inc. Annette Tumolo - Bio-Rad Laboratories, Inc. An...
Source: SeekingAlpha
Date: May, 08 2018 22:57
Bio-Rad Labs beats by $0.10, beats on revenue
Bio-Rad Labs (NYSE: BIO ): Q1 EPS of $1.17 beats by $0.10 . More news on: Bio-Rad Laboratories, Inc., Earnings news and commentary, Tech stocks news, Read more ...
Source: SeekingAlpha
Date: May, 08 2018 17:57
Bio-Rad Reports First Quarter 2018 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2018. First-quarter 2018 net sales were $551.5 million, an increase of 10.3 percent compared...
Source: Business Wire
Date: May, 08 2018 16:25
Bio-Rad to Report First-Quarter 2018 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the first quarter 2018 on Tuesday, May 8, 2018, following the close of the market. The company will discuss these results in a confere...
Source: Business Wire
Date: April, 18 2018 16:24
Detailed Research: Economic Perspectives on CTS, Lindblad Expeditions, AmeriGas Partners, BBX Capital, Bio-Rad Laboratories, and Inter Parfums - What Drives Growth in Today's Competitive Landscape
NEW YORK, March 23, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CTS Corporation (NYSE:CTS), Lindblad Expeditions Holdings Inc. (NASDAQ:L...
Source: GlobeNewswire
Date: March, 23 2018 08:30
Bio-Rad receives non-compliance notice from NYSE over 10-K delay
Bio-Rad Laboratories (NYSE: BIO ) reports that, as expected, it has received notice from the New York Stock Exchange (NYSE) that it in no longer in compliance with listing requirements due to the delay in filing its 2017 financial statements. More news on: Bio-Rad Laboratories, Inc., Hea...
Source: SeekingAlpha
Date: March, 22 2018 07:40
Bio-Rad Laboratories, Inc. Receives Expected NYSE Notice Regarding Late Form 10-K Filing
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it had received an expected notice from the New York Stock Exchange (the “NYSE”) stating that the Company is not in compliance with t...
Source: Business Wire
Date: March, 22 2018 07:00
If You Took On More Risk: Week 14
Safety First: race car driver Leilani Munter and her helmet (Credit: Autokult ) Investing With A Helmet On, But Driving Faster Recently, I posted the returns from the two portfolios I shared with subscribers in the 14th week of my Bulletproof Investing service at the end of August ( P...
Source: SeekingAlpha
Date: March, 08 2018 00:21
Bio-Rad to Present at Barclays Global Healthcare Conference 2018 on March 14
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Christine Tsingos, Executive Vice President and CFO, will present at the Barclays Global Healthcare Confere...
Source: Business Wire
Date: March, 05 2018 21:05
Bio-Rad Laboratories (BIO) Q4 2017 Results - Earnings Call Transcript
Bio-Rad Laboratories, Inc. (BIO) Q4 2017 Earnings Call February 27, 2018 5:00 pm ET Executives Ronald W. Hutton - Bio-Rad Laboratories, Inc. Christine A. Tsingos - Bio-Rad Laboratories, Inc. John Hertia - Bio-Rad Laboratories, Inc. John Goetz - Bio-Rad Laboratories, Inc. Anne...
Source: SeekingAlpha
Date: February, 27 2018 20:47

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-17291.26286.82291.26284.20391,342
2017-11-07260.99262.22263.77257.59302,396
2017-11-06261.42259.82265.88258.5479348,043
2017-11-03241.11261.42262.49236.34746,393
2017-11-02218.00216.94220.97214.44258,014

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1711165616.9207Cover
2018-08-167421,96837.7033Short
2018-08-1558483270.1923Short
2018-08-141,9062,69270.8024Short
2018-08-134441,54528.7379Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BIO.


About Bio-Rad Laboratories, Inc. (NYSE: BIO)

Logo for Bio-Rad Laboratories, Inc. (NYSE: BIO)

Not available

 

Contact Information

 

 

Current Management

  • David Schwartz / President, CEO
  • James J. Bennett / COO
  • Thomas L. Braje / CFO
  • Sanford S. Wadler / Secretary

Current Share Structure

  • Market Cap: $7,039,406,967 - 05/11/2018
  • Issue and Outstanding: 24,701,407 - 04/10/2018

 


Recent Filings from (NYSE: BIO)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: May, 04 2018
Specialized Disclosure Report
Filing Type: SDFiling Source: edgar
Filing Date: May, 04 2018
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 18 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 16 2018
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: March, 02 2018

 

 


Daily Technical Chart for (NYSE: BIO)

Daily Technical Chart for (NYSE: BIO)


Stay tuned for daily updates and more on (NYSE: BIO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NYSE: BIO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BIO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of BIO and does not buy, sell, or trade any shares of BIO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/